Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHACAINE vs ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Articaine hydrochloride is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. Levonordefrin is a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors to produce local vasoconstriction, reducing absorption of the anesthetic and prolonging its effect.
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
Local anesthesia for dental procedures requiring infiltration or nerve block anesthesia
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
For local anesthesia: 1-5 m L of 2% solution (20 mg/m L) with levonordefrin 1:20,000, infiltrated locally; maximum single dose: 3.5 mg/kg (not to exceed 200 mg total).
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Articaine: approximately 1-2 hours (terminal half-life). Levonordefrin: not separately reported; vasoconstrictor effect duration supports anesthetic action. Clinical context: half-life is short, reflecting rapid metabolism by plasma esterases; clinical duration of anesthesia is prolonged by levonordefrin.
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Articaine is metabolized primarily by plasma esterases (butyrylcholinesterase) to its inactive metabolite articainic acid; levonordefrin is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Renal: primarily as metabolites (hydroxy derivatives) and unchanged drug; approximately 90% eliminated in urine as metabolites, <5% unchanged. Biliary/fecal: minor, <10%.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Articaine: approximately 70-80% bound, primarily to albumin. Levonordefrin: not reported.
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Articaine: Vd ~1.0 L/kg. Clinical meaning: moderate distribution into total body water, consistent with local anesthetic profile.
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
Not applicable for local anesthetic; administered parenterally (infiltration/block). By submucosal injection:100% systemically available (though redistributes locally).
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of metabolites.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: No adjustment. Child-Pugh B: Consider 50% dose reduction. Child-Pugh C: Avoid use or reduce dose by 75%; monitor for systemic toxicity.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
Weight-based: 0.5-1.0 mg/kg per injection site, not to exceed 3.5 mg/kg total; maximum single dose 200 mg. Adjust for age and body weight; use lower concentrations (1:100,000 epinephrine equivalent).
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
Reduce dose by 20-50% due to increased risk of cardiovascular and central nervous system effects; consider lower concentration and slower administration.
There is no FDA black box warning for ALPHACAINE.
None
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Risk of methemoglobinemia, especially with higher doses, in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or exposure to oxidizing agents,Cardiovascular effects due to levonordefrin, including hypertension, hypotension, tachycardia, and cardiac arrhythmias; use caution in patients with cardiovascular disease, hypertension, or hyperthyroidism,Allergic reactions including anaphylaxis have been reported,Systemic toxicity due to inadvertent intravascular injection; observe proper injection technique,Use caution in patients with impaired liver function or severe renal impairment
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
Hypersensitivity to articaine, levonordefrin, or any component of the formulation,Hypersensitivity to amide-type local anesthetics or sympathomimetic amines,Severe or uncontrolled hypertension,Concurrent use of MAO inhibitors or within 14 days of discontinuation (due to risk of hypertensive crisis)
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
No significant food interactions. Avoid alcohol consumption for at least 24 hours after the procedure as it may increase the risk of bleeding at the injection site.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: Limited human data, animal studies suggest risk of fetal cardiovascular abnormalities at high doses. Second/third trimesters: May cause uteroplacental vasoconstriction and fetal hypoxia; avoid use during labor due to risk of maternal hypertension and fetal bradycardia.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
Minimal excretion into breast milk; M/P ratio unknown. Levonordefrin has low oral bioavailability. Considered compatible with breastfeeding; monitor infant for irritability or tachycardia. Avoid application to nipples.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
No standard dose adjustment required. Use lowest effective dose and shortest duration. Increased plasma volume in pregnancy may slightly reduce peak concentrations, but no dose adjustment is routinely recommended. Avoid use in preeclampsia or severe hypertension.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a dental anesthetic containing articaine HCl 4% with epinephrine 1:100,000. Levonordefrin is a vasoconstrictor added to prolong local anesthesia. Avoid use in patients with sulfite sensitivity (articaine contains sodium metabisulfite). Maximum dose: 7 mg/kg (articaine) and not to exceed 0.5 mg levonordefrin per appointment. Do not inject into inflamed or infected tissues due to increased absorption. Aspirate before injection to prevent intravascular administration.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
You may experience numbness in your mouth, lips, and tongue for several hours after the injection; avoid eating or drinking hot liquids until sensation returns to prevent burns.,Do not chew on the numb area to avoid accidental injury.,If you have a history of sulfite allergy, inform your dentist before the procedure.,Contact your dentist immediately if you experience severe headache, rapid heartbeat, or difficulty breathing after the injection.,This medication can cause temporary dizziness or lightheadedness; avoid driving until the effects have worn off.
No interactions on record
"Levonordefrin, a vasoconstrictor with beta-agonist activity, may counteract the beta-blocking effects of pindolol, leading to unopposed alpha-adrenergic stimulation and potential hypertensive crisis. Additionally, pindolol's intrinsic sympathomimetic activity (ISA) may interact with levonordefrin, increasing the risk of cardiac arrhythmias and AV block due to conflicting adrenergic signaling. Clinically, this can result in severe hypertension, bradycardia, or heart block, especially in patients with underlying cardiovascular disease."
"Mianserin, a tetracyclic antidepressant with potent alpha-2-adrenergic receptor antagonism, can reduce the vasopressor response to Levonordefrin, a direct-acting alpha-1 adrenergic agonist. This interaction occurs because Mianserin blocks presynaptic alpha-2 receptors, leading to increased norepinephrine release and potential receptor desensitization, as well as possible competitive antagonism at the alpha-1 receptor. Clinically, this may result in diminished efficacy of Levonordefrin when used as a local vasoconstrictor during dental or surgical procedures, potentially leading to inadequate hemostasis or reduced local anesthesia duration."
"Levonordefrin, a sympathomimetic amine with alpha- and beta-adrenergic agonist activity, can enhance the negative dromotropic effect of arotinolol, a non-selective beta-blocker with intrinsic sympathomimetic activity. This results in additive depression of atrioventricular (AV) nodal conduction, potentially leading to prolonged PR interval, second- or third-degree AV block, and symptomatic bradycardia. Clinically, patients may present with dizziness, syncope, or hemodynamic instability, particularly in those with pre-existing conduction abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHACAINE vs ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN, answered by our medical review team.
ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a Local Anesthetic with Vasoconstrictor that works by Articaine hydrochloride is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. Levonordefrin is a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors to produce local vasoconstriction, reducing absorption of the anesthetic and prolonging its effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHACAINE and ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. The standard adult dose of ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is: For local anesthesia: 1-5 m L of 2% solution (20 mg/m L) with levonordefrin 1:20,000, infiltrated locally; maximum single dose: 3.5 mg/kg (not to exceed 200 mg total).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHACAINE and ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data, animal studies suggest risk of fetal cardiovascular abnormalities at high doses. Second/third trimesters: May cause u. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.